K. Ogurtsova, J. D. Da-rocha-fernandes, Y. Huang, U. Linnenkamp, L. Guariguata et al., IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for, Diabetes Res Clin Pract, vol.128, pp.40-50, 2015.

S. M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, vol.339, issue.4, pp.229-263, 1998.

P. Gaede, H. Lund-andersen, H. H. Parving, and O. Pedersen, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, vol.358, issue.6, pp.580-91, 2008.

D. Ettehad, C. A. Emdin, A. Kiran, S. G. Anderson, T. Callender et al., Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, vol.2016, pp.957-67, 10022.

D. Fitchett, B. Zinman, C. Wanner, J. M. Lachin, S. Hantel et al.,

H. J. Woerle, U. C. Broedl, and S. E. Inzucchi, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial, Eur Heart J, vol.37, issue.19, pp.1526-1560, 2016.

A. Sharma, L. B. Cooper, M. Fiuzat, R. J. Mentz, J. P. Ferreira et al.,

A. C. Moses, C. O'connor, and F. Zannad, Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus, JACC Heart Fail, vol.6, issue.10, pp.813-822, 2018.

K. Smolina, F. L. Wright, M. Rayner, and M. J. Goldacre, Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study, Bmj, vol.344, p.8059, 2012.

M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott et al.,

J. F. Kuder, H. Wang, T. Liu, S. M. Wasserman, P. S. Sever et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, N Engl J Med, vol.376, issue.18, pp.1713-1722, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01896445

J. P. Ferreira, N. Girerd, S. Alshalash, M. A. Konstam, and F. Zannad, Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges, Eur Heart J, 2016.

C. Cameron, D. Coyle, T. Richter, S. Kelly, K. Gauthier et al., Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation, BMJ Open, vol.4, issue.6, p.4301, 2014.

S. J. Pocock, C. A. Ariti, J. J. Mcmurray, A. Maggioni, L. Kober et al., Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies, Eur Heart J, vol.34, issue.19, pp.1404-1417, 2013.

A. A. Voors, W. Ouwerkerk, F. Zannad, D. J. Van-veldhuisen, N. J. Samani et al., Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure, Eur J Heart Fail, 2017.

E. Wolsk, B. Claggett, M. A. Pfeffer, R. Diaz, K. Dickstein et al.,

E. F. Lewis, A. P. Maggioni, J. J. Mcmurray, J. L. Probstfield, M. C. Riddle et al., Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus, J Am Heart Assoc, vol.2017, issue.6, p.6

B. M. Everett, M. M. Brooks, H. E. Vlachos, B. R. Chaitman, R. L. Frye et al., Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes, N Engl J Med, vol.373, issue.7, pp.610-630, 2015.

W. B. White, C. P. Cannon, S. R. Heller, S. E. Nissen, R. M. Bergenstal et al.,

A. T. Perez, P. R. Fleck, C. R. Mehta, S. Kupfer, C. Wilson et al., Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, issue.14, pp.1327-1362, 2013.

F. Zannad, C. P. Cannon, W. C. Cushman, G. L. Bakris, V. Menon et al.,

R. Mehta, C. R. Kupfer, S. Wilson, C. Lam, H. White et al., Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.385, issue.9982, pp.2067-76, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01745763

W. B. White, G. L. Bakris, R. M. Bergenstal, C. P. Cannon, W. C. Cushman et al.,

S. Heller, C. Mehta, S. E. Nissen, A. Perez, C. Wilson et al., EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, issue.4, 2011.

Y. C. Hwang, D. A. Morrow, C. P. Cannon, Y. Liu, R. Bergenstal et al.,

W. Cushman, G. L. Bakris, F. Zannad, and W. B. White, High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial, Diabetes Obes Metab, vol.20, issue.3, pp.654-659, 2018.

W. B. White, F. Jalil, W. C. Cushman, G. L. Bakris, R. Bergenstal et al., Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial, J Am Heart Assoc, vol.7, issue.20, 2018.

M. A. Cavender, W. B. White, P. Jarolim, G. L. Bakris, W. C. Cushman et al., Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients

, Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care), Circulation, vol.2017, issue.20, pp.1911-1921

J. P. Ferreira, N. Girerd, P. Pellicori, K. Duarte, S. Girerd et al.,

B. Pitt, K. Dickstein, L. Jacobs, J. A. Staessen, J. Butler et al., Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives, BMC Med, vol.14, issue.1, p.181, 2016.

G. H. Green and P. J. Diggle, On the operational characteristics of the Benjamini and Hochberg False Discovery Rate procedure, Stat Appl Genet Mol Biol, vol.6, p.27, 2007.

F. Harrell, Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2001.

H. Zhu, J. G. Ibrahim, and Q. Chen, Bayesian Case-deletion Model Complexity and Information Criterion, Stat Interface, vol.7, issue.4, pp.531-542, 2014.

M. J. Leening, M. M. Vedder, J. C. Witteman, M. J. Pencina, and E. W. Steyerberg, Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide, Ann Intern Med, vol.160, issue.2, pp.122-153, 2014.

F. Jp and G. Rj, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999.

J. A. De-lemos, M. H. Drazner, T. Omland, C. R. Ayers, A. Khera et al., Association of troponin T detected with a 20 highly sensitive assay and cardiac structure and mortality risk in the general population, Jama, vol.2010, issue.22, pp.2503-2515

A. Sharma, M. Vaduganathan, J. P. Ferreira, Y. Liu, G. L. Bakris et al.,

W. B. Zannad and F. , Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial, J Am Heart Assoc, vol.2020, issue.1, p.12797
URL : https://hal.archives-ouvertes.fr/hal-02611354

M. Huelsmann, S. Neuhold, M. Resl, G. Strunk, H. Brath et al., PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial, J Am Coll Cardiol, vol.62, issue.15, pp.1365-72, 2013.

V. Ramamurthy, A. P. Yamniuk, E. J. Lawrence, W. Yong, L. A. Schneeweis et al.,

M. Murdock, M. J. Corbett, M. L. Doyle, and S. Sheriff, The structure of the death receptor 4-TNFrelated apoptosis-inducing ligand (DR4-TRAIL) complex, Acta Crystallogr F Struct Biol Commun, vol.71, pp.1273-81, 2015.

S. G. Hymowitz, H. W. Christinger, G. Fuh, M. Ultsch, M. O'connell et al.,

A. Ashkenazi and A. M. De-vos, Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5, Mol Cell, vol.4, issue.4, pp.563-71, 1999.

E. Skau, E. Henriksen, P. Wagner, P. Hedberg, A. Siegbahn et al., GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction

, Eur J Prev Cardiol, vol.2017, issue.15, pp.1576-1583

P. M. Ridker and T. F. Luscher, Anti-inflammatory therapies for cardiovascular disease, Eur Heart J, vol.35, issue.27, pp.1782-91, 2014.

J. P. Ferreira, J. Verdonschot, T. Collier, P. Wang, A. Pizard et al.,

A. Boccanelli, J. Butler, A. Clark, J. G. Cleland, C. Delles et al., , p.21

Y. Heymans, S. Zannad, and F. , Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure, Circ Heart Fail, vol.12, issue.5, p.5897, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02267410

X. W. He, W. L. Li, C. Li, P. Liu, Y. G. Shen et al., Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke, vol.7, p.40994, 2017.

B. Panwar, S. E. Judd, V. G. Wadley, N. S. Jenny, V. J. Howard et al.,

O. M. Gutierrez, Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults, JAMA Cardiol, vol.3, issue.4, pp.318-325, 2018.

H. Hao, X. Li, Q. Li, H. Lin, Z. Chen et al.,

M. Kitakaze and Y. Liao, FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin, Oncotarget, vol.2016, issue.40, pp.64649-64664

H. Liu, D. Luo, Y. Qiu, Y. Huang, C. Chen et al., The Effect of AMBP

. Snps, Their Haplotypes, and Gene-Environment Interactions on the Risk of Atherothrombotic Stroke Among the Chinese Population, Genet Test Mol Biomarkers, vol.23, issue.7, pp.487-494, 2019.

X. Wan, L. Zhang, H. Gu, S. Wang, and X. Liu, The Association of Serum hsCRP and Urinary Alpha1-Microglobulin in Patients with Type 2 Diabetes Mellitus, Biomed Res Int, p.6364390, 2019.

S. E. Inzucchi, B. Zinman, D. Fitchett, C. Wanner, E. Ferrannini et al.,

C. Schmoor, K. Ohneberg, O. E. Johansen, J. T. George, S. Hantel et al., How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, Diabetes Care, vol.41, issue.2, pp.356-363, 2018.

A. F. Hernandez, J. B. Green, S. Janmohamed, R. B. D'agostino, . Sr et al.,

J. J. Mcmurray and S. Del-prato, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebocontrolled trial, Lancet, vol.392, pp.1519-1529, 2018.

F. Cosentino, P. J. Grant, V. Aboyans, C. J. Bailey, A. Ceriello et al.,

M. Valensi, P. Wheeler, and D. C. , ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD, Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes, vol.2020, 2019.

, Diabetes Care, vol.2020, pp.111-134

M. T. Cooney, A. L. Dudina, and I. M. Graham, Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians, J Am Coll Cardiol, vol.54, issue.14, pp.1209-1236, 2009.

, HFH: Clinical model vs. Clinical+BNP+Gal9; MI: Clinical model vs. Clinical+Troponin+FGF23+AMBP; Stroke: Clinical model vs. Clinical+Troponin) and the same clinical variables as described in the Table 1 (Previous HFH, Diabetes duration (per year), Myocardial infarction, eGFR (per ml/min/1.73m2), Stroke, SBP, Hypertension, Atrial fibrillation, CV death/HFH: Clinical model vs. Clinical+BNP+Troponin+TRAILR2

, Figure 1. Multivariable c-index and Bayesian Information Criteria (BIC) for the primary outcome (A) C-index (B) BIC